Infosys Limited (NYSE:INFY) Shares Sold by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. decreased its position in shares of Infosys Limited (NYSE:INFY) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,349 shares of the technology company’s stock after selling 3,000 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Infosys were worth $972,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of INFY. Assetmark Inc. lifted its holdings in shares of Infosys by 37.4% during the third quarter. Assetmark Inc. now owns 25,963 shares of the technology company’s stock worth $578,000 after purchasing an additional 7,066 shares during the period. Baillie Gifford & Co. lifted its holdings in shares of Infosys by 4.6% during the third quarter. Baillie Gifford & Co. now owns 3,089,058 shares of the technology company’s stock worth $68,793,000 after purchasing an additional 135,911 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Infosys by 6,071.1% during the third quarter. Victory Capital Management Inc. now owns 4,739,830 shares of the technology company’s stock worth $105,556,000 after purchasing an additional 4,663,023 shares during the period. Empower Advisory Group LLC lifted its holdings in shares of Infosys by 23.4% during the third quarter. Empower Advisory Group LLC now owns 20,120 shares of the technology company’s stock worth $448,000 after purchasing an additional 3,820 shares during the period. Finally, D Orazio & Associates Inc. lifted its holdings in shares of Infosys by 9.1% during the third quarter. D Orazio & Associates Inc. now owns 16,068 shares of the technology company’s stock worth $358,000 after purchasing an additional 1,344 shares during the period. Institutional investors and hedge funds own 16.20% of the company’s stock.

Infosys Price Performance

Infosys stock opened at $18.51 on Thursday. The stock has a market capitalization of $76.65 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 3.50 and a beta of 1.01. Infosys Limited has a 12 month low of $16.04 and a 12 month high of $23.63. The business has a 50 day simple moving average of $21.42 and a 200-day simple moving average of $22.13.

Infosys (NYSE:INFY) last posted its quarterly earnings data on Thursday, January 16th. The technology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. Infosys had a return on equity of 31.60% and a net margin of 17.28%. During the same period in the previous year, the firm earned $0.18 earnings per share. On average, equities research analysts anticipate that Infosys Limited will post 0.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on INFY. Hsbc Global Res raised Infosys from a “hold” rating to a “strong-buy” rating in a report on Monday, December 9th. StockNews.com downgraded Infosys from a “buy” rating to a “hold” rating in a report on Monday. HSBC raised Infosys from a “hold” rating to a “buy” rating in a report on Monday, December 9th. CLSA raised Infosys from a “hold” rating to an “outperform” rating in a report on Friday, March 7th. Finally, Guggenheim reissued a “neutral” rating on shares of Infosys in a report on Friday, January 17th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $20.22.

Infosys Company Profile

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication, Energy, Utilities, Resources, and Services, Manufacturing, Hi-Tech, Life Sciences, and All Other.